<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029856</url>
  </required_header>
  <id_info>
    <org_study_id>2019nCoV-102</org_study_id>
    <nct_id>NCT05029856</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults</brief_title>
  <official_title>A Randomized, Observer-Blinded, Phase 1/2 Study With an Open-Label Group to Evaluate the Safety and Immunogenicity of SII Vaccine Constructs Based on SARS-CoV-2 Variants in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novavax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novavax</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, observer-blinded, Phase 1/2 study with an open-label group to evaluate&#xD;
      the safety and immunogenicity of 3 novel SARS-CoV-2 variant vaccine constructs adjuvanted&#xD;
      with Matrix-M1 adjuvant. Investigational products will include a monovalent SII SARS-CoV-2&#xD;
      B.1.351 (Beta) variant vaccine (SII B.1.351), a bivalent SII vaccine containing antigen for&#xD;
      both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 (SII Bivalent), and a&#xD;
      monovalent SII SARS-CoV-2 B.1.617.2 (Delta) variant vaccine (SII B.1.617.2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 4, 2022</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as GMT</measure>
    <time_frame>Day 14 and Day 35</time_frame>
    <description>(MN50) geometric mean titers (GMTs) to the SARS-CoV-2 B.1.351 (Beta) variant at Day 14 (one-dose regimen; Groups C and D) and Day 35 (two-dose regimen; Groups A and B);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs</measure>
    <time_frame>Day 14 and Day 35</time_frame>
    <description>Seroconversion rates (SCRs) or seroresponse rates (SRRs) (proportion of participants who achieve ≥ 4-fold increase from baseline) in MN50 titer concentrations to the SARS-CoV-2 B.1.351 (Beta) variant following their last vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as GMT</measure>
    <time_frame>Day 14 and Day 35</time_frame>
    <description>Neutralizing antibody MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variant at Day 14 (one-dose regimen; Group H) and Day 35 (two-dose regimen; Group G);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as SCRs/SRRs</measure>
    <time_frame>Day 14 and Day 35</time_frame>
    <description>SCRs/SRRs (proportion of participants who achieve ≥ 4-fold increase from baseline) in MN50 titer concentrations to the SARS-CoV-2 Delta variant following their last vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, duration, and severity of solicited local and systemic adverse events (AEs)</measure>
    <time_frame>Day 0 to Day 7</time_frame>
    <description>Incidence, duration, and severity of solicited local and systemic adverse events (AEs) for 7 days following each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, duration, severity, and relationship of unsolicited AEs through 28 days</measure>
    <time_frame>Day 0 to Day 28</time_frame>
    <description>Incidence, duration, severity, and relationship of unsolicited AEs through 28 days after the last vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and relationship of medically attended adverse events (MAAEs), adverse events of special interest (AESIs) (predefined list), and serious adverse events (SAEs)</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>Incidence and relationship of medically attended adverse events (MAAEs), adverse events of special interest (AESIs) (predefined list), and serious adverse events (SAEs) throughout the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in previously vaccinated patients</measure>
    <time_frame>Day 0 to Day 189</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 14, and 189 in previously vaccinated individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in participants seronegative at baseline</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 21, 35, and 217 in participants seronegative at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in previously vaccinated patients</measure>
    <time_frame>Day 0 to Day 189</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 14, and 189 in previously vaccinated individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in participants seronegative at baseline.</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 21, 35, and 217 in participants seronegative at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in participants seronegative at baseline</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 21, 35, and 217 in participants seronegative at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in previously vaccinated participants</measure>
    <time_frame>Day 0 to Day 189</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 14, and 189 in previously vaccinated individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as SCRs/ SRRs in participants seronegative at baseline</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 21, 35, and 217 in participants seronegative at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as SCRs/ SRRs in previously vaccinated participants</measure>
    <time_frame>Day 0 to Day 189</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 14, and 189 in previously vaccinated individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in previously vaccinated participants</measure>
    <time_frame>Day 0 to Day 189</time_frame>
    <description>IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 14, and 189 in previously vaccinated individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in participants seronegative at baseline</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 21, 35, and 217 in participants seronegative at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG geometric mean concentrations (GMCs) to the B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein in participants seronegative at baseline</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 21, 35, and 217 in participants seronegative at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG geometric mean concentrations (GMCs) to the B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein in previously vaccinated participants</measure>
    <time_frame>Day 0 to Day 189</time_frame>
    <description>IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 14, and 189 in previously vaccinated individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in previously vaccinated participants</measure>
    <time_frame>Day 0 to Day 189</time_frame>
    <description>GMTs to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 14, and 189 in previously vaccinated individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in participants seronegative at baseline</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>GMTs to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 21, 35, and 217 in participants seronegative at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in previously vaccinated participants</measure>
    <time_frame>Day 0 to Day 189</time_frame>
    <description>GMTs to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 14, and 189 in previously vaccinated individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in participants seronegative at baseline</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>GMTs to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 14, and 189 at Days 0, 21, 35, and 217 in participants seronegative at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in participants seronegative at baseline</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein and at Days 0, 21, 35, and 217 in participants seronegative at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in previously vaccinated participants</measure>
    <time_frame>Day 0 to Day 189</time_frame>
    <description>GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein and at Days 0, 14, and 189 in previously vaccinated individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as SCRs/SRRs in participants seronegative at baseline</measure>
    <time_frame>Day 0 to Day 217</time_frame>
    <description>GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein and at Days 0, 21, 35, and 217 in participants seronegative at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as SCRs/SRRs in previously vaccinated participants</measure>
    <time_frame>Day 0 to Day 189</time_frame>
    <description>GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein and at Days 0, 14, and 189 in previously vaccinated individuals</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Group A- SII B.1.351 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of 3 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B- SII B.1.351 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of 5 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C- SII B.1.351 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 3 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D - SII B.1.351 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 5 μg SII B.1.351 Vaccine + 50 μg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E -SII Bivalent Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of 6 μg SII Bivalent Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F- SII Bivalent Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of 10 μg SII Bivalent Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of 5 μg SII B.1.617.2 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 doses of 5 μg SII B.1.617.2 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose on Days 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SII B.1.351</intervention_name>
    <description>Intramuscular (deltoid) injections of 3 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,&#xD;
1 or 2 doses:1 on Day 0 and ± 1 on Day 21.</description>
    <arm_group_label>Group A- SII B.1.351 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_label>Group C- SII B.1.351 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <other_name>(Monovalent B.1.351 [Beta] variant strain vaccine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SII B.1.351</intervention_name>
    <description>Intramuscular (deltoid) injections of 5 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,&#xD;
1 or 2 doses:1 on Day 0 and ± 1 on Day 21.</description>
    <arm_group_label>Group B- SII B.1.351 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_label>Group D - SII B.1.351 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <other_name>(Monovalent B.1.351 [Beta] variant strain vaccine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SII Bivalent</intervention_name>
    <description>Intramuscular (deltoid) injections of 6 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.</description>
    <arm_group_label>Group E -SII Bivalent Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <other_name>(Bivalent ancestral and B.1.351 [Beta] variant strain vaccine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SII Bivalent</intervention_name>
    <description>Intramuscular (deltoid) injections of 10 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.</description>
    <arm_group_label>Group F- SII Bivalent Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <other_name>(Bivalent ancestral and B.1.351 [Beta] variant strain vaccine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SII B.1.617.2</intervention_name>
    <description>Intramuscular (deltoid) injections of 5 μg SII B.1.617.2 and 50 μg Matrix-M1 Adjuvant,&#xD;
1 or 2 doses:1 on Day 0 and ± 1 on Day 21.</description>
    <arm_group_label>Group G- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_label>Group H- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant</arm_group_label>
    <other_name>(Monovalent B.1.617.2 [Delta] variant strain vaccine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 18 to 64 years of age, inclusive, at screening.&#xD;
&#xD;
          2. Willing and able to give informed consent prior to study enrollment and to comply with&#xD;
             study procedures.&#xD;
&#xD;
          3. Female participants of childbearing potential (defined as any participant who has&#xD;
             experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral&#xD;
             tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at&#xD;
             least 12 consecutive months]) must agree to be heterosexually inactive from at least&#xD;
             28 days prior to enrollment and through the end of the study OR agree to consistently&#xD;
             use a medically acceptable method of contraception listed below from at least 28 days&#xD;
             prior to enrollment and through the end of the study.&#xD;
&#xD;
               1. Condoms (male or female) with spermicide (if acceptable in country)&#xD;
&#xD;
               2. Diaphragm with spermicide&#xD;
&#xD;
               3. Cervical cap with spermicide&#xD;
&#xD;
               4. Intrauterine device&#xD;
&#xD;
               5. Oral or patch contraceptives&#xD;
&#xD;
               6. Norplant®, Depo-Provera®, or other in-country regulatory approved contraceptive&#xD;
                  method that is designed to protect against pregnancy&#xD;
&#xD;
               7. Abstinence, as a form of contraception, is acceptable if in line with the&#xD;
                  participant's lifestyle&#xD;
&#xD;
          4. Is medically stable, as determined by the investigator (based on a review of health&#xD;
             status, vital signs [to include body temperature], medical history, and targeted&#xD;
             physical examination [to include body weight]). Vital signs must be within medically&#xD;
             acceptable ranges prior to the first vaccination.&#xD;
&#xD;
          5. Agrees to not participate in any other SARS-CoV-2 prevention or treatment trials for&#xD;
             the duration of the study.&#xD;
&#xD;
             For previously vaccinated Participants (Groups C, D and H):&#xD;
&#xD;
          6. Documented receipt of 2 doses of the investigational Novavax vaccine with Matrix-M1&#xD;
             adjuvant (NVX-CoV2373) administered approximately 21 days apart or 2 doses of a&#xD;
             TGA-authorized/approved COVID-19 vaccine administered at least 60 days prior to first&#xD;
             study vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        If an individual meets any of the following criteria, he or she is ineligible for this&#xD;
        study:&#xD;
&#xD;
          1. History of laboratory-confirmed (by PCR or serology to SARS-CoV-2) COVID-19 infection&#xD;
             at any time prior to randomization/enrollment.&#xD;
&#xD;
          2. Previous receipt of any investigational or authorized/approved vaccine, prophylactic&#xD;
             or therapeutic agent for the prevention or treatment of SARS-CoV-2 infection, except&#xD;
             for previously vaccinated participants.&#xD;
&#xD;
          3. Participation in research involving receipt of investigational products&#xD;
             (drug/biologic/device) within 90 days prior to first study vaccination.&#xD;
&#xD;
          4. Received influenza vaccination within 14 days prior to first study vaccination, or any&#xD;
             other vaccine within 30 days prior to the first study vaccination.&#xD;
&#xD;
          5. Any known allergies to products contained in the investigational product.&#xD;
&#xD;
          6. Any history of anaphylaxis to any prior vaccine.&#xD;
&#xD;
          7. Autoimmune or immunodeficiency disease/condition (iatrogenic or congenital) requiring&#xD;
             ongoing immunomodulatory therapy.&#xD;
&#xD;
          8. Chronic administration (defined as &gt; 14 continuous days) of immunosuppressants,&#xD;
             systemic glucocorticoids, or other immune-modifying drugs within 90 days prior to&#xD;
             first study vaccination.&#xD;
&#xD;
          9. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90&#xD;
             days prior to first study vaccination.&#xD;
&#xD;
         10. Active cancer (malignancy) on therapy within 3 years prior to first study vaccination&#xD;
             (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo&#xD;
             maligna and uterine cervical carcinoma in situ without evidence of disease, at the&#xD;
             discretion of the investigator).&#xD;
&#xD;
         11. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to&#xD;
             the end of study.&#xD;
&#xD;
         12. Suspected or known history of alcohol abuse or drug addiction within 2 years prior to&#xD;
             the first study vaccine dose that, in the opinion of the investigator, might interfere&#xD;
             with protocol compliance.&#xD;
&#xD;
         13. Any other condition that, in the opinion of the investigator, would pose a health risk&#xD;
             to the participant if enrolled or could interfere with evaluation of the study vaccine&#xD;
             or interpretation of study results (including neurologic or psychiatric conditions&#xD;
             likely to impair the quality of safety reporting).&#xD;
&#xD;
         14. Study team member or immediate family member of any study team member (inclusive of&#xD;
             Sponsor, CRO, and study site personnel involved in the conduct or planning of the&#xD;
             study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa Golden</last_name>
    <phone>240-368-5445</phone>
    <email>lgolden@novavax.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Paratus Clinical Research - Western Sydney</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Rahul Mohan, Dr</last_name>
      <phone>+61 2 8608 8666</phone>
      <email>rahul.mohan@paratusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Research - Central Coast</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Kim Joshua</last_name>
      <phone>+61 2 4393 3852</phone>
      <email>joshua.kim@paratusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Network (ACRN)</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Ktut Wiradjaja Arya, Dr</last_name>
      <phone>+61 2 8347 0645</phone>
      <email>markarya@acrn.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice - Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark Bloch</last_name>
      <phone>+61 2 9331 7228</phone>
      <email>mark.bloch@holdsworthhouse.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Geelong-Barwon Health</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3320</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Athan Eugene, Prof</last_name>
      <phone>+61 2 8347 0645</phone>
      <email>eugene@barwonhealth.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Louise Murdoch, Dr.</last_name>
      <phone>+ 613 95096166</phone>
      <email>louisemurdoch@emeritusresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

